Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Recommendation of "Buy" from Brokerages

Key Points

• Context Therapeutics Inc. has received an average consensus recommendation of "Buy" from six analysts, with five giving a buy rating and one a strong buy rating.
• The average 12-month price target for Context Therapeutics is $5.25, though recent target prices from analysts vary from $4.00 to $9.00.
• In the most recent quarter, Context Therapeutics reported earnings per share of ($0.09), missing analysts' expectations of ($0.06).

Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) has been assigned an average recommendation of "Buy" from the six analysts that are presently covering the company, MarketBeat.com reports. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $5.25.

Several equities research analysts recently commented on the company. D. Boral Capital reissued a "buy" rating and set a $9.00 target price on shares of Context Therapeutics in a report on Thursday, August 7th. Piper Sandler reissued an "overweight" rating and set a $4.00 target price (down previously from $4.50) on shares of Context Therapeutics in a report on Thursday, June 26th. Finally, HC Wainwright dropped their target price on Context Therapeutics from $5.00 to $4.00 and set a "buy" rating on the stock in a report on Thursday, August 7th.

Context Therapeutics Trading Up 0.1%

CNTX opened at $0.82 on Tuesday. The business's 50 day moving average is $0.78 and its 200-day moving average is $0.75. The stock has a market cap of $73.68 million, a PE ratio of -2.28 and a beta of 1.90. Context Therapeutics has a twelve month low of $0.49 and a twelve month high of $2.59.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.03). As a group, analysts forecast that Context Therapeutics will post -0.51 EPS for the current year.

Institutional Investors Weigh In On Context Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC bought a new stake in Context Therapeutics during the fourth quarter worth approximately $29,000. Citadel Advisors LLC acquired a new position in Context Therapeutics in the fourth quarter worth approximately $31,000. Shay Capital LLC acquired a new position in Context Therapeutics in the fourth quarter worth approximately $52,000. Millennium Management LLC grew its position in Context Therapeutics by 24.2% in the fourth quarter. Millennium Management LLC now owns 178,718 shares of the company's stock worth $188,000 after buying an additional 34,835 shares during the last quarter. Finally, MPM Bioimpact LLC acquired a new position in Context Therapeutics in the fourth quarter worth approximately $15,441,000. Institutional investors own 14.03% of the company's stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.